BUZZ-Immuneering soars on positive trial data for pancreatic cancer therapy

** Shares of therapy developer Immuneering IMRX.O rise 101.7% to $4.76 premarket

** Co says its therapy, IMM-1-104, showed an overall response rate of 43% in combination with gemcitabine during a mid-stage trial for patients with pancreatic cancer

** IMRX will expand the trial to include three combination treatment arms this year in addition to the existing three arms

** Co says it expects further trial data in Q2 2025

** Up to last close, stock down 64.8% in the previous 12 months

(Reporting by Christy Santhosh)

((Christy.Santhosh@thomsonreuters.com))